Florbetapir F18

DRUG5 trials

Sponsors

Eli Lilly & Co., Avid Radiopharmaceuticals, Sanofi, Eli Lilly and Company

Conditions

Alzheimer DiseaseAlzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental DisordersAlzheimers DiseaseAmyloidDementia Alzheimer's TypeHealthy VolunteersPlaque, Amyloid

Phase 1

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

Not yet recruitingNCT07787182

Eli Lilly and CompanyHealthy Volunteers, Alzheimer Disease, Amyloid +1

Start: 2026-09-01End: 2028-01-01Target: 68Updated: 2026-08-26

A Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease

Not yet recruitingNCT07787169

Eli Lilly and CompanyAlzheimer Disease, Amyloid, Plaque, Amyloid +1

Start: 2026-09-01End: 2028-07-01Target: 179Updated: 2026-08-27

Phase 2

Safety Study of Sargramostim in Treating Patients With Mild Cognitive Impairment Due to Alzheimer's Disease

WithdrawnNCT02667496

SanofiDementia Alzheimer's Type

Start: 2016-11-30End: 2017-03-31Updated: 2017-04-07

Phase 3

I5T-MC-AACO: Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease

RecruitingCTIS2025-522340-40-00

Eli Lilly & Co.Alzheimer Disease Dementia Brain Diseases Central Nervous System Diseases Nervous System Diseases Tauopathies Neurodegenerative Diseases Neurocognitive Disorders Mental Disorders

Start: 2025-12-04Target: 170Updated: 2026-01-19

Phase 4

The Feasibility of Florbetapir Quantitation

CompletedNCT01946243

Avid RadiopharmaceuticalsAlzheimers Disease

Start: 2013-08-31End: 2014-04-30Updated: 2015-06-29